Correspondence  by unknown
effect on the level of circulating catecholamines or inhibition of
phosphodiesterase.
Seven of our patients had junctional bradycardia before the
administration of theophylline, and all converted to sinus rhythm. We
previously described the conversion of junctional to sinus rhythm with
theophylline (11). However, the majority of patients included in this
study presented with sinus bradycardia. Eventually, permanent pace-
maker implantation was required in 3 of our 29 patients, all due to
recurrent sinus bradycardia. Because our surgeons use biatrial anasta-
mosis, one can speculate that these “theophylline-resistant” patients
had mechanical trauma to the sinus node. Regardless of the mecha-
nism of action of theophylline in these patients, on the basis of these
observations, we propose that theophylline can be useful for early
posttransplantation bradyarrhythmias to increase heart rate, facilitate
withdrawal of positive chronotropic support and avoid unnecessary
permanent pacemaker implantation.
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Clinical Value of a New Doppler Index in
Cardiac Amyloidosis
In a recent issue of the Journal Tei et al. (1) proposed a new Doppler
index for combined assessment of systolic and diastolic myocardial
performance in cardiac amyloidosis. Using a ratio consisting of the
sum of the isovolumetric contraction time and the isovolumetric
relaxation time divided by the ejection time, they tried to show
retrospectively that patients with cardiac amyloidosis can be stratified
according to probability of cardiac death and overall mortality.
We would like to comment on two important aspects of this study.
First, it is our opinion that such strong prognostic conclusions cannot
be drawn from the patient population selected, which included three
each with familial and senile cardiac amyloidosis. Although cardiac
involvement is echocardiographically indistinguishable between pa-
tients with primary amyloidosis and those with the familial or senile
forms, the survival pattern is considerably better in the latter two
(2–4). Given the small number of patients who were still alive after
divergence of the two survival curves in Figures 5 and 6, a possibly
unequal distribution of the six patients with nonprimary amyloidosis
might cause severe selection bias, rendering the prognostic conclusions
questionable. Therefore, we would suggest reanalyzing these survival
curves after exclusion of patients with familial and senile amyloidosis.
Even if a survival difference persisted, this index should be studied
prospectively in patients with primary amyloidosis before its optimistic
introduction into clinical medicine.
Second, we are uncertain whether this Doppler index adds anything
to previous noninvasive indexes of systolic function alone. The two
most powerful variables of this index are the isovolumetric contraction
time and the ejection time. Given the narrow range of possible
variation, changes in the isovolumetric relaxation time exert only a
minor influence on the magnitude of the index. Indeed as the authors
point out, a previous study from their institution (5) showed only a
slight increase in isovolumetric relaxation time in the subgroup with
early cardiac amyloidosis, whereas in the advanced subgroup this
variable was not different from normal values. Because the electrome-
chanical delay is constant within a wide range of heart rates, changes
in isovolumetric contraction time correspond to changes in the
preejection period. Therefore, this new Doppler index behaves very
much like the ratio of preejection period and ejection time. When left
ventricular dysfunction occurs, regardless of the cause, preejection
period lengthens, ejection time shortens, and the ratio increases.
Numerous studies (6–8) have shown the value of this ratio in defining
the severity of cardiac dysfunction, as well as its prognostic implica-
tions in various types of heart disease. Therefore, the new Doppler
index of Tei et al. (1) seems to be merely a reappraisal of systolic time
intervals in patients with myocardial disease and largely ignores
Doppler measures of diastolic function (e.g., deceleration time and
early/late peak velocity ratio of left ventricular inflow), which were
recently shown (9) to be independent prognostic indicators in patients
with cardiac involvement in primary amyloidosis.
JOHANN REISINGER, MD
RODNEY H. FALK, MD, FACC
Section of Cardiology
Boston University Medical Center
91 East Concord Street, MAT 6
Boston, Massachusetts 02118
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Reply
As Falk states, cardiac infiltration is common in patients with primary
amyloidosis and those with the familial or senile forms, but the
prognosis is quite different between the groups (1). However, echo-
cardiograms are morphologically indistinguishable, with similar left
and right ventricular wall thickness, left ventricular volume and
ejection fraction. Thus, in our study patients, the echocardiographic
images from patients with senile or familial amyloidosis were indistin-
guishable from those with primary amyloidosis. The diagnosis of
cardiac amyloidosis was based on the presence of typical echocardio-
graphic features and was further established by the presence of
amyloid at biopsy. Because the patients were selected on the basis of
the presence of typical echocardiographic features of cardiac amyloid-
osis, we did not exclude patients with senile or familial amyloidosis
from the analysis. The purpose of the study was to analyze whether the
Doppler index could be used to characterize the impact of amyloid
infiltration on cardiac function and therefore predict the outcome.
However, we also observed similar results in an analysis of the 39
patients with primary amyloidosis: The group with an index greater
than the median value had a higher mortality risk than the group with
an index lower than the median value.
Systolic dysfunction is reflected in prolongation of the preejection
phase and shortening of the ejection phase of the cardiac cycle (2).
Diastolic dysfunction is reflected in alterations of the flow velocity
pattern of the left ventricle. A previous study (3) demonstrated
prolongation of the isovolumetric relaxation time in early amyloidosis
only, but the interval tended to be shortened because of increased left
atrial pressure in the advanced stage with restrictive filling. However,
we found that the isovolumetric relaxation time was prolonged, even in
the later stages of amyloid involvement (4). This may be explained by
the shortened ejection time, with earlier closure of the aortic valve, and
the negative peak rate of left ventricular pressure, which is significantly
abnormal in more advanced stages of cardiac amyloidosis (5). Thus,
our results demonstrate that the net result is prolongation of the
isovolumetric relaxation time, even in advanced cardiac amyloidosis,
and the new index combining systolic and diastolic time intervals was
the most powerful indicator of clinical outcome in patients with cardiac
amyloidosis compared with previously reported Doppler echocardio-
graphic variables. We have also demonstrated that the new Doppler
index was more powerful than the preejection period/ejection time and
isovolumetric contraction time/ejection time ratios at differentiating
mild and severe left ventricular dysfunction (6), probably due to the
frequent coexistence of systolic and diastolic dysfunction (7). In
addition, we have found that the index combining systolic and diastolic
time intervals was the most powerful predictor of clinical outcome in
patients with idiopathic dilated cardiomyopathy (unpublished data)
and right ventricular dysfunction (8). We would like to emphasize that
the new index is simple, reproducible and easily obtained by conven-
tional Doppler echocardiography and is a useful predictor of clinical
outcome in patients with both systolic and diastolic dysfunction.
CHUWA TEI, MD
Cardiology Laboratory





1. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo
Clin Proc 1983;58:665–83.
2. Weissler AM, Harris WS, Schoenfeld CG. Systolic time intervals in heart failure in man.
Circulation 1968;37:149–59.
3. Klein AL, Hatle LK, Taliercio CP, et al. Prognostic significance of Doppler measures of
diastolic function in cardiac amyloidosis. Circulation 1991;83:808–16.
4. Tei C, Dujardin KS, Hodge DO, Kyle RA, Tajik AM, Seward JB. Doppler index combining
systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am
Coll Cardiol 1996;28:658–64.
5. Swanton RH, Brooksbey IAB, Davies MJ, Coltart DJ, Jenkins BS, Webb-Peploe MM.
Systolic and diastolic ventricular function in cardiac amyloidosis. Am J Cardiol 1977;39:
658–64.
6. Tei C, Lieng HL, Hodge DO, et al. New index of combined systolic and diastolic myocardial
performance: a simple and reproducible measure of cardiac function—a study in normals
and dilated cardiomyopathy. J Cardiol 1995;26:357–66.
7. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation 1990;81 Suppl
III:III-1–7.
8. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for the assessment
of global right ventricular function. J Am Soc Echocardiogr 1996;9:838–47.
Digoxin Reduces Cardiac Sympathetic
Activity in Severe Congestive Heart Failure
The study by Newton et al. (1) is original, well done and provocative.
However, I find it difficult to accept the conclusion that the study
supports the idea that neurohormonal inhibition explains any benefi-
cial effects of digitalis in heart failure. For the group as a whole,
digoxin clearly had no effect on either total body or cardiac norepi-
nephrine spillover. Making sense of the differential responses in the
two subgroups is statistically problematic given the difference in group
sizes and the fact that increased spillover was also seen in the group
with higher wedge pressure. The clinical significance is even more
problematic because it would not be possible to distinguish these
patients without invasive measurements, even if one were to accept the
suggestion that patients with high wedge pressure might benefit. If we
have learned anything about mechanisms in heart failure in the past
decade, it would be that agents that either increase the activity or
potentiate the effects of the sympathetic nervous system are to be
avoided. At best, on the basis of the data from our own group (2) and
Newton et al., digoxin is neutral with regard to the sympathetic nervous
system, with the disturbing suggestion from Newton et al. that it may
also exert adverse effects in some patients. Perhaps the complexity of
the neurohormonal effects of digoxin in part explains why the DIG trial
failed to find any beneficial effect on mortality. Digoxin clearly has
vagotonic effects in heart failure (2,3), but I believe that it is time to
stop speculating about the sympathoinhibitory effects of this agent
because in the end, the only real evidence to support this mechanism
in human heart failure comes from observations by Ferguson et al. (4)
using very large, significantly pressor doses of deslanoside without
appropriate controls.
STEVEN R. GOLDSMITH, MD
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